BACKGROUND: Although Fingolimod (FGD) and Natalizumab (NTZ) appear to be effective in relapsing-remitting multiple sclerosis (RRMS), they have never been directly compared in a randomized clinical trial (RCT). METHODS AND FINDINGS: We evaluated the comparative efficacy of FGD vs. NTZ using a meta-analytical approach. Data from placebo-controlled RCTs was used for indirect comparisons and observational data was utilized for head-to-head comparisons. We identified 3 RCTs (2498 patients) and 5 observational studies (2576 patients). NTZ was associated with a greater reduction in the 2-year annualized relapse rate (ARR; SMDindirect = -0.24;95% CI: from -0.44 to -0.04; p = 0.005) and with the probability of no disease activity at 2 years (ORindirect:1.82, 95% CI: from 1.05 to 3.15) compared to FGD, while no differences between the two therapies were found in the proportion of patients who remained relapse-free (ORindirect = 1.20;95% CI: from 0.84 to 1.71) and those with disability progression (ORindirect = 0.76;95% CI: from 0.48 to 1.21) at 2 years. In the analysis of observational data, we found no significant differences between NTZ and FGD in the 2-year ARR (SMD = -0.05; 95% CI: from -0.26 to 0.16), and 2-year disability progression (OR:1.08;95% CI: from 0.77 to 1.52). However, NTZ-treated patients were more likely to remain relapse-free at 2-years compared to FGD (OR: 2.19;95% CI: from 1.15 to 4.18; p = z0.020). CONCLUSIONS: Indirect analyses of RCT data and head-to-head comparisons of observational findings indicate that NTZ may be more effective than FGD in terms of disease activity reduction in patients with RRMS. However, head-to-head RCTs are required to independently confirm this preliminary observation.

1st Department of Neurology Eginition Hospital School of Medicine University of Athens Athens Greece

2nd Department of Neurology AHEPA University Hospital Aristotelion University of Thessaloniki Thessaloniki Macedonia Greece

2nd Department of Neurology Attikon Hospital School of Medicine University of Athens Athens Greece

Department of Hygiene and Epidemiology School of Medicine University of Ioannina Ioannina Greece

Department of Neurology Alexandroupolis University Hospital Democritus University of Thrace Alexandroupolis Greece

Department of Neurology School of Medicine University of Ioannina Ioannina Greece

Department of Neurology The University of Tennessee Health Science Center Memphis Tennessee United States of America

Department of Neurology University Hospital of Larissa University of Thessaly Larissa Greece

Department of Neurology University of Patras Medical School Patras Greece

Department of Primary Education University of Ioannina Ioannina Greece

International Clinical Research Center Department of Neurology St Anne's University Hospital in Brno Brno Czech Republic

See more in PubMed

Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Papathanasopoulos P, et al. The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0144538 10.1371/journal.pone.0144538 PubMed DOI PMC

Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013;40:307–23. 10.1017/s0317167100014244 PubMed DOI

Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler. 2009;15:50–8. 10.1177/1352458508096687 PubMed DOI

Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis—a review of approved medications. Eur J Neurol. 2016;23 Suppl 1:18–27. 10.1111/ene.12883 PubMed DOI PMC

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62:e1–34. 10.1016/j.jclinepi.2009.06.006 PubMed DOI

EMEA: Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. Doc. Ref. CPMP/EWP/561/98 Rev. 1, 16 November 2006

Sormani MP, Signori A, Siri P, De Stefano N. Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler. 2013;19:466–74 10.1177/1352458512457841 PubMed DOI

Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–60. 10.1016/S1474-4422(09)70021-3 PubMed DOI

Cohen J. Statistical Power Analysis for the Behavioral Sciences Hillsdale, New Jersey, 1988. Lawrence Erlbaum Associates: Routledge.

Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Papathanasopoulos P, et al. The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2015;8:193–202. 10.1177/1756285615600381 PubMed DOI PMC

Deeks JJ, Higgins JP, Altman DG. Chapter 9.4.6: Combining dichotomous and continuous outcomes. Cochrane Handbook for Systematic Reviews of Interventions.website. Available: http://handbook.cochrane.org/chapter_9/9_4_6_combining_dichotomous_and_continuous_outcomes.htm. Updated March 2011. Accessed February 23th, 2016.

Borenstein M, Hedges LV, Higgins JPT and Rothstein HR. Chapeter 19: Subgroup Analyses, in Introduction to Meta-Analysis, John Wiley & Sons, Ltd, Chichester, UK: 10.1002/9780470743386.ch19 DOI

Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions website. Available: http://handbook.cochrane.org/chapter_9/9_analysing_data_and_undertaking_meta_analyses.htm. Updated March 2011. Accessed February 4th, 2014.

Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–91. 10.1016/s0895-4356(97)00049-8 PubMed DOI

Salanti G. Indirect and mixed-treatment comparison, network, or multiple- treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis school. Research Synthesis Methods 2012;3:80–97. 10.1002/jrsm.1037 PubMed DOI

Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354:899–910. 10.1056/NEJMoa044397 PubMed DOI

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401. 10.1056/NEJMoa0909494 PubMed DOI

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13:545–56. 10.1016/S1474-4422(14)70049-3 PubMed DOI

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, et al. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. Neurology. 2016;86:771–8. 10.1212/WNL.0000000000002395 PubMed DOI PMC

Braune S, Lang M, Bergmann A; NTC Study Group. Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort. J Neurol. 2013;260:2981–5. 10.1007/s00415-013-7082-0 PubMed DOI PMC

Gajofatto A, Bianchi MR, Deotto L, Benedetti MD. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. Eur Neurol. 2014;72:173–80. 10.1159/000361044 PubMed DOI

Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol. 2015;77:425–35. 10.1002/ana.24339 PubMed DOI

Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg Sørensen P. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Mult Scler. 2016. April 7 pii: 1352458516643393. [Epub ahead of print] 10.1177/1352458516643393 PubMed DOI

Kappos L, De Stefano N, Freedman MS, Cree BA, Radue EW, Sprenger T, et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2015. November 19 pii: 1352458515616701. [Epub ahead of print] 10.1177/1352458515616701 PubMed DOI PMC

Röver C, Nicholas R, Straube S, Friede T. Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression. PLoS One. 2015;10:e0137052 10.1371/journal.pone.0137052 PubMed DOI PMC

Lavorgna L, Bonavita S, Ippolito D, Lanzillo R, Salemi G, Patti F, et al. Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Mult Scler. 2014;20:220–6. 10.1177/1352458513494958 PubMed DOI

Kappos L, Kuhle J, Multanen J, Kremenchutzky M, Verdun di Cantogno E, Cornelisse P, et al. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. J Neurol Neurosurg Psychiatry. 2015;86:1202–7. 10.1136/jnnp-2014-310024 PubMed DOI PMC

Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology. 2011;77:1684–90. 10.1212/WNL.0b013e31823648b9 PubMed DOI

Uher T, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, et al. Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. Mult Scler. 2016. April 6 pii: 1352458516642314. [Epub ahead of print] 10.1177/1352458516642314 PubMed DOI

Filippi M, Preziosa P, Rocca MA. Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink? Curr Opin Neurol. 2014;27:290–9. 10.1097/WCO.0000000000000095 PubMed DOI

Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol. 1991;29:548–55. 10.1002/ana.410290515 PubMed DOI

Bermel RA, Naismith RT. Using MRI to make informed clinical decisions in multiple sclerosis care. Curr Opin Neurol. 2015;28:244–9. 10.1097/WCO.0000000000000204 PubMed DOI

Losseff NA, Miller DH, Kidd D, Thompson AJ. The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis—preliminary results. Mult Scler. 2001;7:23–5. 10.1177/135245850100700105 PubMed DOI

Alroughani RA, Akhtar S, Ahmed SF, Al-Hashel JY. Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort. Int J Neurosci. 2015;125:831–7. 10.3109/00207454.2014.976641 PubMed DOI

Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72:152–8. 10.1001/jamaneurol.2014.3537 PubMed DOI

Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC. Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord. 2015;8:3–13. 10.1177/1756285614560733 PubMed DOI PMC

Frisell T, Forsberg L, Nordin N, Kiesel C, Alfredsson L, Askling J, et al. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. Mult Scler. 2016;22:85–93. 10.1177/1352458515579216 PubMed DOI

O'Day K, Meyer K, Stafkey-Mailey D, Watson C. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden. J Med Econ. 2015;18:295–302. 10.3111/13696998.2014.991786 PubMed DOI

Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26:617–27. 10.2165/00019053-200826070-00008 PubMed DOI

Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015;9: CD011381 10.1002/9780470743386.ch19 PubMed DOI PMC

Mavridis D, Giannatsi M, Cipriani A, Salanti G. A primer on network meta-analysis with emphasis on mental health. Evid Based Ment Health. 2015;18:40–6. 10.1136/eb-2015-102088 PubMed DOI PMC

Conway DS, Cohen JA. Natalizumab and fingolimod: insight into their relative efficacies in clinical practice. Mult Scler. 2014;20:1280–1. 10.1177/1352458514535283 PubMed DOI

Hauser SL, Johnston SC. Balancing risk and reward: the question of natalizumab. Ann Neurol. 2009;66:A7–8. 10.1002/ana.21873 PubMed DOI